Help control the disease by delaying tumor growth, as demonstrated by a significant improvement in PFS and ORR—backed by improved OS
PFS=progression-free survival; ORR=objective response rate; OS=overall survival; CI=confidence interval.
*The percentage of events at the time of analysis was 89% (558 patients) and 93% (583 patients) in the CYRAMZA plus docetaxel and placebo plus docetaxel arms, respectively.
‡Intent-to-treat (ITT) population. Disease progression and tumor response were assessed by investigators in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.2
ORR=complete + partial response; does not include stable disease.
The phase III REVEL trial evaluated the efficacy and safety of CYRAMZA plus docetaxel vs placebo plus docetaxel in patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy. Major efficacy outcome measure was overall survival. Supportive efficacy outcome measures were progression-free survival and objective response rate. All patients were required to have Eastern Cooperative Oncology Group performance status 0 or 1. Patients were randomized 1:1 (N=1253) to receive either CYRAMZA 10 mg/kg or placebo, in combination with docetaxel at 75 mg/m2 every 21 days.1
NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®)—Category 2A3
NCCN Guidelines® for NSCLC V.4.2016 recommend ramucirumab (CYRAMZA) in combination with docetaxel as a second-line (subsequent) treatment option for metastatic NSCLC. Category 2A: Based upon lower-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate.Click here to watch Dr. Mark Socinski speak about the REVEL trial results
- CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd.
- Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet . 2014;384(9944):665-673. Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.4.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed January 28, 2016. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN content are trademarks owned by the National Comprehensive Cancer Network, Inc.